# Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

> **NCT01156532** · — · TERMINATED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 30 (actual)

## Conditions studied

- Moderate to Severe Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01156532
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** This study was prematurely terminated due to low enrollment and not for safety reasons.
- **Last updated:** 2014-08-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156532, "Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01156532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*